NASDAQ:KALA KALA BIO (KALA) Stock Price, News & Analysis $4.24 +0.06 (+1.44%) Closing price 04:00 PM EasternExtended Trading$4.21 -0.03 (-0.71%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About KALA BIO Stock (NASDAQ:KALA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get KALA BIO alerts:Sign Up Key Stats Today's Range$4.20▼$4.3850-Day Range$2.94▼$4.7452-Week Range$2.92▼$11.20Volume16,523 shsAverage Volume95,102 shsMarket Capitalization$27.35 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingBuy Company OverviewKALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Read More… KALA BIO Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreKALA MarketRank™: KALA BIO scored higher than 50% of companies evaluated by MarketBeat, and ranked 264th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKALA BIO has only been the subject of 2 research reports in the past 90 days.Read more about KALA BIO's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KALA BIO is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KALA BIO is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKALA BIO has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KALA BIO's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.71% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in KALA BIO has recently increased by 2.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKALA BIO does not currently pay a dividend.Dividend GrowthKALA BIO does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.35 Percentage of Shares Shorted5.71% of the float of KALA BIO has been sold short.Short Interest Ratio / Days to CoverKALA BIO has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in KALA BIO has recently increased by 2.47%, indicating that investor sentiment is decreasing. News and Social MediaN/ANews SentimentN/A Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,857.00 in company stock.Percentage Held by InsidersOnly 8.32% of the stock of KALA BIO is held by insiders.Percentage Held by InstitutionsOnly 24.61% of the stock of KALA BIO is held by institutions.Read more about KALA BIO's insider trading history. Receive KALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter. Email Address KALA Stock News HeadlinesMary Reumuth Sells 2,850 Shares of KALA BIO, Inc. (NASDAQ:KALA) StockJune 5, 2025 | insidertrades.comKALA BIO to Present at Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.June 18, 2025 | Crypto 101 Media (Ad)KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | finance.yahoo.comKALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | markets.businessinsider.comKALA BIO to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | finance.yahoo.comKala Bio announces CEO departure, appoints interim leaderFebruary 13, 2025 | msn.comKALA BIO, Inc.: KALA BIO Announces Chief Executive Officer TransitionFebruary 12, 2025 | finanznachrichten.deSee More Headlines KALA Stock Analysis - Frequently Asked Questions How have KALA shares performed this year? KALA BIO's stock was trading at $6.94 at the beginning of the year. Since then, KALA stock has decreased by 38.1% and is now trading at $4.2950. View the best growth stocks for 2025 here. How were KALA BIO's earnings last quarter? KALA BIO, Inc. (NASDAQ:KALA) posted its quarterly earnings data on Friday, March, 28th. The company reported ($1.74) EPS for the quarter, topping analysts' consensus estimates of ($2.28) by $0.54. When did KALA BIO's stock split? KALA BIO's stock reverse split on Friday, October 21st 2022. The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did KALA BIO IPO? KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. Who are KALA BIO's major shareholders? KALA BIO's top institutional investors include ADAR1 Capital Management LLC (4.63%), Woodline Partners LP (4.01%), AIGH Capital Management LLC (3.04%) and Readystate Asset Management LP (0.66%). Insiders that own company stock include Bros Advisors Lp Baker, Mark T Iwicki, Romulus K Brazzell, Todd Bazemore, Eric Trachtenberg, Darius Kharabi and Mary Reumuth. View institutional ownership trends. How do I buy shares of KALA BIO? Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of KALA BIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL). Company Calendar Last Earnings3/28/2025Today6/18/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALA CIK1479419 Webwww.kalarx.com Phone(781) 996-5252Fax781-642-0399Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+214.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($8.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-369.29% Return on Assets-64.99% Debt Debt-to-Equity Ratio3.19 Current Ratio1.99 Quick Ratio1.99 Sales & Book Value Annual Sales$3.89 million Price / Sales7.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book2.13Miscellaneous Outstanding Shares6,450,000Free Float5,915,000Market Cap$27.70 million OptionableNot Optionable Beta-1.98 Social Links 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:KALA) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | SponsoredThe largest wealth transfer in American history. And you're the target.This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KALA BIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KALA BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.